ClinicalTrials.gg

Program

ABBV-519

A development code.

In AbbVie's pipeline, CD19. Its studies are mostly in Lupus Erythematosus, Systemic, led by AbbVie.

Furthest: phase 1, since May 20, 20261 company-led study, 1 open or runningNext primary completion: Jan 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since May 20, 2026May 20, 2026Jan 2029phase 1 · NCT07607964
  • Named in AbbVie’s own pipeline as ABBV-519, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2026First study: phase 1 study in Lupus Erythematosus, SystemicFirst studyNCT07607964 · 30 planned · United States, Japan

Ahead

  1. Jan 2029Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07607964

TargetBeta

“CD19”the company's pipeline, read by Claude · source

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07607964Lupus Erythematosus, Systemic · United States, Japan1RecruitingJan 202930

How it is read

Names in the registry

  • “ABBV-519”, 2 entries

Codes read as this program: ABBV519.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.